Global Biomarkers Technologies, Markets and Companies Projections Report 2017 – PR Newswire (press release)

Posted on by

This report describes different types of biomarkers and their discovery using various -omics technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery of biomarkers and new tests are also based on biomarker.

This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological responses to a therapeutic intervention. Tests based on biomarkers have been around for more than half a century, but interest in their application for diagnostics and drug discovery as well as development has increased remarkably since the beginning of the 21st century.

Currently the most important applications of biomarkers are in drug discovery and development. The role of biomarkers in various therapeutic areas particularly cancer, cardiovascular diseases and disorders of the central nervous system, is described. Biomarkers are useful not only for diagnosis of some of these diseases but also for understanding the pathomechanism as well as a basis for development of therapeutics.

Biomarkers will facilitate the combination of therapeutics with diagnostics and will thus play an important role in the development of personalized medicine. Biomarkers play a role in use of pharmacogenetics, pharmacogenomics and pharmacoproteomics for development of personalized medicine.

Many of the regulatory issues concerning biomarkers are related to genomics, proteomics, molecular diagnostics and pharmacogenomics/pharmacogenetics. Validation of biomarkers and their role in clinical trials is discussed.

Biomarker markets are estimated from 2016 to 2026 according to share of markets for various technologies and applications: proteomics, metabolomics, molecular diagnostics, drug discovery, clinical trials, and bioinformatics. Market values are further split according to therapeutic applications and major geographical areas. Unfulfilled needs in biomarkers are identified as well as the drivers for biomarker markets. Challenges facing the biomarker industry and strategies for developing biomarker markets are discussed.

A large number of companies with varying technical backgrounds are involved in biomarkers and 304 of these are profiled in part 2 of the report with classification into various categories.These also include major pharmaceutical companies. There is tabulation of 467 collaborations between companies and additional academic collaborations are mentioned in the individual profiles of companies. The report is supplemented by 1,200 references, 77 tables and 20 figures

Key Topics Covered:

Part 1: Technologies & Markets

Executive Summary

1. Introduction

2. Technologies for Discovery of Biomarkers

3. Biomarkers and Molecular Diagnostics

4. Biomarkers for Drug Discovery & Development

5. Role of Biomarkers in Healthcare

6. Biomarkers of Cancer

7. Biomarkers of Disorders of the Nervous System

8. Biomarkers of Cardiovascular Disorders

9. Biomarkers & Personalized Medicine

10. Biomarkers and Regulatory issues

11. Markets for Biomarkers

12. References

Part II: Companies

13. Companies

For more information about this report visit https://www.researchandmarkets.com/research/4nrrhw/biomarkers

Source: Jain PharmaBiotech

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-biomarkers-technologies-markets-and-companies-projections-report-2017-300483376.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the rest here:
Global Biomarkers Technologies, Markets and Companies Projections Report 2017 - PR Newswire (press release)

10th International Conference on Genomics and Pharmacogenomics – Technology Networks

Posted on by

Theme: Advanced Approaches in Genomics and Pharmacogenomics

It gives us immense pleasure to announce the conference that is 10th International Conference on Genomics & Pharmacogenomics.

Genomics 2018 will provide a perfect platform to all the Scientists, Researchers, Students and Business Delegates to approach and deliver all the attendees about the latest scientific advancements on the respective sphere.

Genomics 2018 Genomics is an area within genetics that concerns the sequencing and analysis of an organisms genome. Genomics also involves the study of intragenomic processes such as epistasis, heterosis and pleiotropy as well as the interactions between loci and alleles within the genome. The fields of molecular biology and genetics are mainly concerned with the study of the role and function of single genes, a major topic in todays biomedical research. By contrast, genomics does not involve single gene research unless the purpose is to understand a single genes effects in context of the entire genome

Conference Highlights: Cancer Genomics, Functional Genomics, Next Generation Sequencing, Biomarkers & Molecular Markers, Pharmacogenomics & Personalized Medicine, Clinical Genomics, Micro RNAm, RNA Analysis, Bioinformatics in Genomics, Comparative Genomics, Plant Genomics, Genome Engineering, Microbial Genomics, Future trends in Genomics, Genome Medicine, and Genomics Market

Link of the conference: http://genomics.conferenceseries.com/

Conference Mail ID: genomics@conferenceseries.net, genomics@geneticconferences.com

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

Visit link:
10th International Conference on Genomics and Pharmacogenomics - Technology Networks

Updated Scientific Program | Euro Personalized Medicine …

Posted on by

Sessions and Tracks

The 6thEuropeanConference on Predictive Preventive and Personalized Medicine & Molecular Diagnostics will be held on September 14-15, 2017 at Edinburgh, Scotland will be organized around the themeUnleashing the novel approaches in advancing Personalized Medicinewhichcomprises 23 Sessions/Tracksto outline the theme of the conference organized by conferenceseries LLCConferences. The main aim of the conference is to highlight the achievements and innovations in the various fields of Personalized Medicine across the globe.

Track 1: Molecular Diagnostics in Personalized Medicine

In personalized medicine molecular diagnostics is used for analysing of biological markers and also analysing by applying molecular biology to medical testing .This technique is used to diagnose and monitor disease,detect risk in individual patients .DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule .SNP genotyping is the measurement of genetic variations of single nucleotide polymorphism (SNPs) . which is the measurement of more general genetic variation.Gene expression profiling is used for the measurement of the activity of thousands of genes at once.

Relevant conferences:

InternationalConference on Medical Imaging & Diagnosis,May 09 - 10, 2016 ,Chicago,US. InternationalCancer Study & Therapy Conference, 46 April 2016 ,Baltimore,United States.Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany . Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.

Related Associations:

Alzheimers and Dementia Testing for Earlier Diagnosis

Association for Molecular Pathology Establishes New Standard for Clinical Utility of Molecular Diagnostics

British In Vitro Diagnostics Association (BIVDA)

California Life Sciences Association- Molecular Diagnostics

American Board of Clinical Chemistry

Molecular Diagnostics Laboratory

Association for Molecular pathology

Track2: Biomarkers Personalized Medicine

In personalized medicine biomarkers and biological marker generally refers to a measurableindicator of some biological state or condition. This word refer to a substance the presence of which indicates the existence of aliving organism. Biochemical biomarkers are often used inclinical trials, Biomarkers used for personalized medicine are typically categorized as either prognostic or predictive .In , a biomarkersis a molecule that allows the detection and isolation of a particular cell type. A biomarker indicates a change in state of a protein that correlates with the risk or progression of a disease . Biomarkers are useful in a number of ways, including measuring the progress of disease. Biomarkers also used in early diagnosis, disease prevention, drug target identification, drug response etc.

Relevant conferences :

International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany . Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Conference on Medical Imaging & Diagnosis , May 09 - 10, 2016 , Chicago, US. .International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome ,Italy.

Related Associations:

ALS research Association

European society of cardiology

American Association of Pharmaceutical Scientists

American Board of Clinical Chemistry

Track3: Pharmacogenetic in Personalized Medicine

In personalized medicine pharmacogenetics is the study of inherited genetic differences in drug metabolic pathways which can affect the drug responses, like therapeutic effect as well as adverse effect. Inter- and intra-individual variation in gene expression and its function.In oncology, pharmacogenetics refers to germline mutations and pharmacogenomics is study the somatic mutations in tumoral DNA leading to alteration in drug response

Relevant conferences :

Nanomaterials and Nanobiotechnolog Conference April 21-23, 2016 Dubai, UAE. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy. European Human Genetics Conference 2016 , May 21-24, 2016, Barcelona, Spain. World congress on Translation genomics,28 feb - 2 march, 2016,houstan, USA. Personalised Medicine Conference ,1-2 June,2016, Brussels, Belgium.

Related Associations:

European Society of Pharmacogenomics and Personalized Medicine

American Society of Human Genetics

Hungarian Society of Personalized Medicine

American Society for Investigative Pathology

Association for Molecular Pathology

Track4: Pharmacogenomics in Personalized Medicine

Pharmacogenomics is the study of the role of genetics in drug response. It deals with the influence of acquired and inheritedgeneticvariation on drug response, drug absorption distribution, metabolism, and elimination ,as well as drug receptor target effects . Pharmacogenomics is often used interchangeably with pharmacogenetics.Pharmacogenomics is used for the detection of the individual genetic variation with drug responses pharmacogenetics focuses on single drug-gene interactions, incorporating genomics and epigenetics while dealing with the effects of multiple genes on drug response

Relevant conferences :

International Conference on Medical Imaging & Diagnosis , May 09 - 10, 2016 , Chicago, US.International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany . Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome ,Italy.

Related Associations:

Genetics societies

Canadian Association of genetics Counsellors

European Cytogeneticists Association

Human genome organization

International Genetic Epidemiology Society

British Society of Genetic Medicine

Track5: Pharmacoproteomics in Personalized Medicine

The proteome is the entire set of proteins it is expressed by genome , cell, tissue, or organism at a certain time. More specifically, it is a combined of proteins and genomes . Proteomics is the study of the proteome. A cellular proteome is the collection of proteins present in a particular cell type and it exposure to harmone stimulation . It can also be useful to consider an organisms complete proteome, which can be conceptualized as the complete set of proteins from all of the various cellular proteomes. Proteome used to refer to the collection of proteins in certain sub-cellular biological systems.

Relevant conferences:

International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy .European Human Genetics Conference 2016 , May 21-24, 2016, Barcelona, Spain .World congress on Translation genomics , 28feb - 2 march ,2016, houstan,USA . Personalised Medicine Conference ,1-2 June,2016, Brussels, Belgium. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States.

Related Associations:

International precision medicine Associates

International Society of Personalized Medicine

British Society for Proteome Research

European Proteomics Association

Swiss Proteomics Society

Japan Society for clinical Proteomics

Track6: Metabolomics in Personalized Medicine

Metabolomics is defined as the chemical processes involving of metabolites. Metabolomics is the study of the unique chemical fingerprints. The metabolome refers to the collection of all metabolites in a biological cell, tissue, organ or organism. mRNA gene expression data and proteomic analyses reveals the set of gene products in the cell. One of the challenges of system biology and functional genomics is to integrate proteomic ,transcriptomic, and metabolomic information to provide a cellular biology.

Relevant conferences :

Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy.

Related Associations:

Metabolomics Society

The Metabolomics Standards Initiative (MSI)

Metabolomics for a Low Carbon Society (METABOLOMICS)

Swiss Metabolomics Society

Metabolomics Research Group (MRG)

Track7: Personalized in Health Care

Personalized medicineis aMedical Practice that separates patients into different groups with medical decisions, practices, interventions and products being tailored to the individual patient based on their predicted response or risk of disease. The words of personalized medicine,precision medicine,stratified medicineand P4 medicine are used interchangeably .

Relevant conferences :

International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE . International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore , United States. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016,Snowbird,United States . International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore , United States. International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy. European Human Genetics Conference 2016 , May 21-24, 2016, Barcelona, Spain.

Related Associations:

American Health Care Association

Florida Health Care Association

OHCA Oregon Health Care Association

Texas Health care Association

Washington Health Care Association

Track8: Non- genomics Personalized Medicine

Epigenomics is a set of epigenetic modifications on the genetic material of a cell is called as the epigenome. Epigenetics are reversible modifications on a cells DNA that affect the gene expression without altering the DNA sequence. Epigenetic modifications are important role in the gene expression and regulation, that are involved in the numerous cellular processes such as tumorigenesis.

Relevant conferences:

Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird,United States.International Conference on Medical Imaging & Diagnosis , May 09 - 10, 2016 , Chicago, US.International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy.

Related Associations:

Genome Wide Association Studies (GWAS)

Genetics societies

Canadian Association of genetics Counsellors

European Cytogeneticists Association

Human genome organization

International Genetic Epidemiology Society

British Society of Genetic Medicine

German society of Human Genetics

Track9: Personalized Biological Therapies

Biological therapy refers to the use of medication , specifically target an immune or genetic mediator of disease. Even for diseases of unknown cause of molecules that are involved in the disease process have been identified, and can be targeted for biological therapy. which are mainly cytokines , are directly involved in the immune system .Biological therapy used for the management of cancer , autoimmune disease, and diseases of unknown cause that result in symptoms due to immune related mechanisms.

Relevant conferences :

International Conference on Medical Imaging & Diagnosis , May 09 - 10, 2016 , Chicago, US.International conference on HIV/AIDS ,STDs & STIs from November 30-December 02, 2015 at Hilton Atlanta Airport, Atlanta, USA. Conference on Human Genetics 2015 October 06-10, 2015, Baltimore, United States. International Conference on Genomics and pharmacogenomics during September 12-14, 2016 Berlin, Germany. Nanomaterials and Nanobiotechnology Conference April 21-23, 2016 Dubai, UAE. Congress on Heart Failure Genetics, Genomics and Epigenetics 37 April 2016 , Snowbird, United States. International Cancer Study & Therapy Conference, 46 April 2016 , Baltimore, United States.International Congress on Human Genetics and Genomics , Dec 8-9,2016, Rome , Italy.

Related Associations:

Human Biology Association

American Biological Safety Association

Society for Conversation Biology

Association for Tropical Biology

American Institute of Biological Sciences

American Society for Microbiology

Track10: Personalized Management of Cancer Therapy

More here:
Updated Scientific Program | Euro Personalized Medicine ...

Pharmacogenomics Market: Improving Healthcare Infrastructure in APAC Incrementing Demand – Edition Truth

Posted on by

Therapeutic applications such as cardiology, oncology, neurological disorder, and pain management will keep the global Pharmacogenomics Market in good stead in the near future.

Rising usage of Pharmacogenomics in drug discovery processes, prevalence of various infectious as well as non-infectious diseases, growing demand for personalized drugs, and increasing awareness regarding the benefits of customized medication are some of the key factors augmenting the demand in the global pharmacogenomics market. The concept of pharmacogenomics has the ability to serve subpopulations on the basis of susceptibility to particular disease, as individual response of a drug depends on genetic composition. Rise in investment in research and development and advancement in technology pharmacogenomics engineering to create in vivo environment are some of the other factors favoring the global pharmacogenomics market. Some of the drugs used for pharmacogenomics tests are thiopurines, warfarin, clopidogrel, abacavir, irinotecan, phenytoin, and carbamazepine. These tests are useful for diseases such as autoimmune or childhood leukemia, excessive clotting disorder, cancer, cardiovascular, HIV, psychiatric and related diseases, and epilepsy.

On the other hand, the lack of consistency in pharmacogenomics products is one of the major hindrance of the expansion of the market. Nevertheless, the vendors operating in the pharmacogenomics market are expected to gain from increased focus on regenerative medicine and increased awareness of organ transplantation.

Technology-wise, the global pharmacogenomics market can be segmented into sequencing such as sanger sequencing, pyrosequencing, and next-generation sequencing, polymerase chain reaction, and other technologies such as electrophoresis and mass spectrometry. In the current scenario of the market, sequencing dominates the market, particularly since the advent of next generation sequencing, which offers high accuracy, increased throughput screening, and speed. Application-wise, the market can be bifurcated into oncology, pain management, cardiology, and neurological disorders.

Geographically, the report studies the potential of pharmacogenomics market in every major region such as North America, Asia Pacific, Europe, and the Middle East and Africa. Currently, North America is most profitable region, gaining most of the demand from the developed countries of the U.S. and Canada. However, Asia Pacific is also expected to increment the demand steadily during the forecast period due to improving healthcare facilities in a number of emerging economies.

Some of the most prominent players operating in the global pharmacogenomics market are GE Healthcare, GlaxoSmithKline, GeneDX, Pfizer, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Abbott Laboratories, Inc., Assurex Health, Affymetrix, Inc., Bayer AG, Illumina, Inc., Merck & Co, Myriad Genetics, Inc., Johnson & Johnson, Pathway Genomics, Teva Pharmaceutical Industries Ltd, Qiagen, Inc., and Thermo Fisher Scientific.

Download a PDF Brochure ofPharmacogenomics Market Research Report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3615

Go here to read the rest:
Pharmacogenomics Market: Improving Healthcare Infrastructure in APAC Incrementing Demand - Edition Truth

PGxOne Pharmacogenomics Test | Admera Health

Posted on by

ACE Inhibitors Benazepril (Lotensin) ACE Captopril (Capoten) ACE AGTR1 Perindopril (Aceon) ACE AGTR1 Quinapril (Accupril) ACE Angiotensin II Receptor Blockers Candesartan (Atacand) AGTR1 Irbesartan (Avapro) ACE Losartan (Cozaar) ABCB1 AGTR1 Antianginal Agent Ranolazine (Ranexa) CYP2D6 Antiarrhythmic Agent Amiodarone (Cordarone) CYP3A4 NOS1AP Digoxin (Lanoxin) ABCB1 Dronedarone (Multaq) CYP3A4 Flecainide (Tambocor) CYP2D6 Propafenone (Rythmol) CYP2D6 Anticoagulants Phenprocoumon (Marcoumar) CYP4F2 Rivaroxaban (Xarelto) CYP3A4 Warfarin (Coumadin) CYP2C9 VKORC1 Antiplatelets Clopidogrel (Plavix) CYP2C19 Ticagrelor (Brilinta) CYP3A4 Beta Blockers Atenolol (Tenormin) ADRA2A Carvedilol (Coreg) CYP2D6 Nebivolol (Bystolic) CYP2D6 Propranolol (Inderal LA) CYP2D6 Metoprolol Tartrate (Lopressor) CYP2D6 Calcium Channel Blockers Amiodarone (Cordarone) NOS1AP Amlodipine (Norvasc) CYP3A4 NOS1AP Diltiazem (Cardizem) CYP3A4 Felodipine (Plendil) CYP3A4 Lercanidipine (Zanidip) CYP3A4 Nifedipine (Adalat) NOS1AP Nisoldipine (Sular) CYP3A4 Nitrendipine (Nitrepin) AGTR1 CYP3A4 Verapamil (Calan) NOS1AP Diuretics Bumetanide (Bumex) ACE Furosemide (Lasix) ACE Hydrochlorothiazide (Microzide) ACE AGTR1 Spironolactone/HCTZ (Aldactazide) ADTR1 ACE Spironolactone (Aldactone) ACE Torasemide (Demadex) ACE Phosphodiesterase Inhibitors Cilostazol (Pletal) CYP3A4 Antilipemic Agent Atorvastatin (Lipitor) ABCB1 APOE CYP3A4 CYP3A5 KIF6 SLCO1B1 Fluvastatin (Lescol) ACE Lovastatin (Mevacor) CYP3A4 CYP3A5 Pitavastatin (Livalo) SLCO1B1 Pravastatin (Pravachol) KIF6 SLCO1B1 Rosuvastatin (Crestor) SLCO1B1 Simvastatin (Zocor) ABCB1 CYP3A4 CYP3A5 SLCO1B1 Atorvastatin/Ezetimibe (Liptruzet) ABCB1 APOE CYP3A4 KIF6 SLOC1B1 Fenofibrate (Tricor) APOE Simvastatin/Ezetimibe (Vytorin) ABCB1 SLCO1B1 Vasodilators Nitroprusside (Nipride) ACE Hydralazine NAT2 Hydralazine/Isosorbide (Bidil) NAT2 Miscellaneous Cardiovascular Agents Ivabradine (Corlanor) CYP3A4 ACE Inhibitors/Diuretics Quinapril/HCTZ (Accuretic) ACE AGTR1 Captopril/HCTZ (Capozide) ACE AGTR1 Benazepril/HCTZ (Lotensin HCT) ACE AGTR1 Lisinopril/HCTZ (Prinzide) AGTR1 Enalapril/HCTZ (Vaseretic) AGTR1 ARBs/Diuretics Candesartan/HCTZ (Atacand HCT) AGTR1 Irbesartan/HCTZ (Avalide) ACE AGTR1 Losartan/HCTZ (Hyzaar) AGTR1 ABCB1 Beta-Blocker/Diuretic Metoprolol/HCTZ (Lopressor HCT) CYP2D6 AGTR1 CCB/ACE Inhibitor Amlodipine/Benazepril (Lotrel) ACE CYP3A4 NO1SAP

Go here to read the rest:
PGxOne Pharmacogenomics Test | Admera Health

BC researchers are exploring the use of genomics to improve drug treatments for people with depression – Yahoo Finance

Posted on by

VANCOUVER, British Columbia, March 13, 2020 (GLOBE NEWSWIRE) -- For people with mental health conditions, finding a medication that works without causing severe side effects is often a matter of trial-and-error. This can contribute to a lower adherence to treatment regimens and poorer health, as well as increased costs to the health care system.

Pharmacogenomics can improve a persons health by helping them know ahead of time whether a drug is likely to be an effective treatment and be safe for them to take without triggering an adverse reaction. This is one of the strongest examples to show how precision health holds real potential to end the trial-and-error approach to therapy.

However, there are still many questions to be answered before there can be wider adoption of pharmacogenomic testing in a clinical setting. In a new $1.5 million project, supported by funding from Genome BC, Genome Canada and the Michael Smith Foundation for Health Research, University of British Columbia researchers, Dr. Stirling Bryan and Dr. Jehannine Austin, are investigating if pharmacogenomic testing should be routinely used in BC for people with depression.

Our goal is to gather the necessary information to assess the improvement in patient health, as well as whether the testing is good value for money for the health system, said Dr. Jehannine Austin. The multidisciplinary team we have assembled includes people with diverse backgrounds and skills, including patient partners with lived experiences.

The work will involve reviewing existing studies to learn from the research of others and collecting BC specific information from the records kept by the health care system. The team will also apply extensive stakeholder engagement, talking to patients, doctors, nurses, pharmacists, counsellors, and others providing care for patients with mental health conditions in BC.

We want to gain insight into the typical experiences of patients, said Dr. Stirling Bryan. This information will be used in a simulation model, where we can count the health benefits to patients and the costs of changing practice to include routine use of pharmacogenomics testing for depression.

Pharmacogenomics shows significant potential for delivering precision health care, said Dr. Ellie Griffith, Sector Director, Health at Genome BC. If the findings indicate that pharmacogenomics testing provides value to both patients and the health care system, this information could be used to bring a positive change to how we care for patients with depression in BC.

MSFHR is committed to partnering on strategic initiatives enabling BC researchers to generate and apply much needed research evidence in areas of high priority to our provinces health system, says Dr. Bev Holmes, President and CEO, Michael Smith Foundation for Health Research.

Genome British Columbia leads genomics innovation on Canadas West Coast and facilitates the integration of genomics into society. A recognized catalyst for government and industry, Genome BC invests in research, entrepreneurship and commercialization in life sciences to address challenges in key sectors such as health, forestry, fisheries and aquaculture, agrifood, energy, mining and environment. Genome BC partners with many national and international public and private funding organizations to drive BCs bioeconomy. http://www.genomebc.ca

Michael Smith Foundation for Health Research (MSFHR), funded by the Province of British Columbia, is BC's health research funding agency. MSFHR helps develop, retain and recruit the talented people whose research improves the health of British Columbians, addresses health system priorities, creates jobs and adds to the knowledge economy. Learn more at http://www.msfhr.org.

Genome Canada is a not-for-profit organization that acts as a catalyst for developing and applying genomics and genomic-based technologies, to create economic and social benefits for Canadians. Genome Canada connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation, and translates discoveries into applications and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries & aquaculture, energy, mining, and the environment. http://www.genomecanada.ca

Story continues

Go here to read the rest:
BC researchers are exploring the use of genomics to improve drug treatments for people with depression - Yahoo Finance

Interpace Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter, Full Year 2019 and Preliminary First Quarter 2020 Financial…

Posted on by

PARSIPPANY, NJ, April 22, 2020 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will release its financial results for the fourth quarter and full year 2019 this afternoon. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at5:00 pm today, Wednesday April 22, 2020 at 5:00 p.m. Eastern time.

The conference call can be accessed as follows:

Date and Time:Wednesday, April 22, 2020 at 5:00 p.m. ETDial-in Number (Domestic):+1 (877) 407-9716Dial-in Number (International):+1 (201) 493-6779Confirmation Number:137025801Webcast Access: http://public.viavid.com/index.php?id=139473

Following the conclusion of the conference call, a replay will be available through May 6, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Companys website at http://www.interpacediagnostics.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Companys website for 90 days.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through the Interpace Diagnostics division, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary versus metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Pharma services, through the Pharma Solutions Division, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advance personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goal of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences website atwww.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement, including the potential adverse impact of the Coronavirus (COVID-19) pandemic, our history of operating losses and the limited revenue generated by our clinical and pharma solutions customers, Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K filed on April 22, 2020. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:Investor RelationsEdison GroupJoseph Green(646) 653-7030jgreen@edisongroup.com

Continued here:
Interpace Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter, Full Year 2019 and Preliminary First Quarter 2020 Financial...

NantOmics and NantHealth Announce Results of Proprietary Machine Vision AI Software Study Demonstrating the Ability to Identify Aggressive Subtypes of…

Posted on by

Feb. 19, 2020 13:00 UTC

Study Published In Breast Cancer Research Shows How Deep-Learning Of Over 650 Breast Cancer Digital Pathology Images And Omics Data Can Be Used Together To Unlock Precise Mechanisms Of Therapy Resistance

CULVER CITY, Calif.--(BUSINESS WIRE)-- NantOmics, LLC, the leader in molecular analysis, and NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today the publication of a peer-reviewed study in Breast Cancer Research, a Springer Nature journal, on a novel AI technique in breast cancer. The study reports on a novel deep-learning system of digital pathology images and omics data used together to more precisely identify mechanisms of therapy resistance.

NantOmics scientists trained a deep-neural network on diagnostic slide images from 443 breast tumors that had previously undergone PAM50 subtyping to classify patches of the tumor images into four major molecular subtypes of breast cancer (basal-like, HER2-enriched, luminal A, and luminal B). The algorithm was then validated and demonstrated the capability to establish accurate breast cancer sub-typing in 222 samples from a retained set of tumors. By focusing the neural-networks attention on cancer-rich regions in the diagnostic images, this deep-learning algorithm identifies patient biopsies that are a mixture of different molecular subtypes, a classification that is less definable from molecular pathology techniques. Patients with heterogeneous biopsies such as mixtures of basal-like and luminal disease have a different survival profile than patients with homogeneous disease, and may potentially benefit from a more tailored therapy regimen.

Breast cancer can be subtyped into at least five distinct disease-types with very different prognoses and responses to therapy. These subtypes are characterized as clinically important, yet are typically only achievable by RNA expression profiling, Dr. Patrick Soon-Shiong, MD, Chairman and CEO of NantHealth explained. With this AI technique we achieved 87 percent accuracy rate in detecting which patients had basal-like breast cancer (i.e., triple negative breast cancer), one of the most aggressive subtypes, he said.

Our analysis builds on our breadth of advanced machine learning technologies to better support providers in therapeutic decision-making and to improve the capabilities of the underlying molecular analysis technology platforms that we use at NantHealth and NantOmics, said Soon-Shiong. Through the advances of machine vision and augmented intelligence, we have developed a rapid and cost-effective deep-learning technique to unlock the rich information in readily-available diagnostic slide images to define subtypes concordant with their underlying molecular designations.

Breast Cancer Research, a Springer Nature journal, is an international, peer-reviewed online journal publishing original research, reviews, editorials and reports in breast cancer. Breast Cancer Research is published by BMC, an open access publisher that produces over 250 scientific journals and according to its website, is the highest ranked breast cancer focused title in the field.

About NantOmics NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular diagnostic and machine learning AI capabilities to provide actionable intelligence and molecularly driven decision support for patients and their providers. NantOmics is the first molecular in vitro diagnostics company to accurately identify mutations and true tumor mutation burden (TMB) from proprietary tumor-normal sequencing. The identified mutations and correlative calculation of true TMB, combined with proprietary expression analysis of immuno-oncology biomarkers and novel deep-learning derived digital pathology solutions, establish the framework for the appropriate use of targeted, chemo- and immunotherapies. NantOmics computational analysis engine, an organically grown, scalable, cloud-based infrastructure capable of processing and storing thousands of genomes per day, uses novel AI tools to combine expression analysis with near real-time genomic variance computing to generate precise N of 1 neoepitope vaccine therapies for cancer patients. For more information please visit http://www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About NantHealth NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealths comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer). For more information, please visit http://www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

Forward-Looking Statements: NantHealth This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words expects, anticipates, believes, intends, estimates, plans, will, outlook and similar expressions. Forward-looking statements are based on managements current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005341/en/

Link:
NantOmics and NantHealth Announce Results of Proprietary Machine Vision AI Software Study Demonstrating the Ability to Identify Aggressive Subtypes of...

Personalized Medicine Market Worth $3.92 Trillion by 2026 – Insights Into Diagnostics, Medical Care, Nutrition & Wellness, and Therapeutics – P&T…

Posted on by

DUBLIN, Feb. 20, 2020 /PRNewswire/ -- The "Global Personalized Medicine Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Personalized Medicine market is expected to reach $3.92 trillion by 2026, growing at a CAGR of 12.1% during the forecast period.

The efficient and advanced technology and higher prevalence of disease are driving the market growth. However, the higher cost of research and developments is hampering the market.

Based on the End-user, the hospital's segment is estimated to have a lucrative growth due to the lower cost personalized medicines availability in the hospitals. As the practice of personalized medicine becomes more widespread, hospitals will also experience the need to adapt. That does not mean every hospital and medical centre should try and drive the science, but they should be open to collaborations to facilitate such work.

The key vendors mentioned are Abbott Laboratories, Affymetrix Incorporated, Agendia N.V, Agilent Technologies, Inc, Amgen, Inc, Asuragen Incorporated, Bayer Healthcare Pharmaceuticals, Llc, Celera Diagnostics LLC, Celgene Corporation, Roche Diagnostics Corporation, Precision Biologics Incorporated, Siemens Healthcare Diagnostics, Inc, Sigma-Aldrich Corporation, Johnson & Johnson, Novartis AG, Decode Genetics Inc., Exact Science Corporation, Exagen Diagnostics Inc., GE Healthcare, and Genelex Corporation.

Key Questions Answered in the Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics3.1 Drivers3.2 Restraints

4 Market Environment

5 Global Personalized Medicine Market, By Product5.1 Introduction5.2 Diagnostics5.3 Personalized Medical Care5.4 Personalized Nutrition & Wellness5.5 Therapeutics

6 Global Personalized Medicine Market, By Technology6.1 Introduction6.2 Metabolomics6.3 Pharmacodynamics6.4 Pharmacogenetics6.5 Pharmacogenomics6.6 Pharmacokinetics6.7 Pharmacoproteomics6.8 Point-of-Care Testing6.9 Stem Cell Therapy

7 Global Personalized Medicine Market, By Therapeutic Area7.1 Introduction7.2 Autoimmune Diseases7.3 Blood Transfusion Safety7.4 Cancer Management7.5 Cardiovascular Diseases (CVD)7.6 Central Nervous System (CNS) Disorders7.7 Coagulation Therapy7.8 Diabetes7.9 Infectious Diseases7.10 Antiviral7.11 Neurology7.12 Psychiatry7.13 Oncology7.14 Immunology7.15 Respiratory

8 Global Personalized Medicine Market, By Distribution Channel8.1 Introduction8.2 Dietary Care Centers8.3 Hospital's Pharmacies8.4 Retail Pharmacies8.5 Other Distribution Channels

9 Global Personalized Medicine Market, By Application9.1 Introduction9.2 Biomarker Identification9.3 Clinical Research Applications9.4 Companion Diagnostics9.5 Health Informatics

10 Global Personalized Medicine Market, By End-user10.1 Introduction10.2 Academic Institutes10.3 Bio and Health Informatics Companies10.4 Clinical Care and Research Laboratories10.5 Contract Research Organizations10.6 Hospitals10.7 Molecular Diagnostic Laboratories and Testing Facilities10.8 Research Laboratories10.9 Service Providers10.10 Partner10.11 Venture Capitalists10.12 Other End-users

11 Global Personalized Medicine Market, By Geography11.1 North America11.2 Europe11.3 Asia-Pacific11.4 South America11.5 Middle East & Africa

12 Strategic Benchmarking

13 Vendors Landscape13.1 Abbott Laboratories13.2 Affymetrix Incorporated13.3 Agendia N.V13.4 Agilent Technologies Inc.13.5 Amgen Inc.13.6 Asuragen Incorporated13.7 Bayer Healthcare Pharmaceuticals, LLC13.8 Celera Diagnostics LLC13.9 Celgene Corporation13.10 Roche Diagnostics Corporation13.11 Precision Biologics Incorporated13.12 Siemens Healthcare Diagnostics Inc.13.13 Sigma-Aldrich Corporation13.14 Johnson & Johnson13.15 Novartis AG13.16 Decode Genetics Inc.13.17 Exact Science Corporation13.18 Exagen Diagnostics Inc.13.19 GE Healthcare13.20 Genelex Corporation

For more information about this report visit https://www.researchandmarkets.com/r/37rw80

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/personalized-medicine-market-worth-3-92-trillion-by-2026---insights-into-diagnostics-medical-care-nutrition--wellness-and-therapeutics-301008591.html

SOURCE Research and Markets

View original post here:
Personalized Medicine Market Worth $3.92 Trillion by 2026 - Insights Into Diagnostics, Medical Care, Nutrition & Wellness, and Therapeutics - P&T...

Sex Differences in Associations Between CYP2D6 Phenotypes and Response | PGPM – Dove Medical Press

Posted on by

Guilherme S Lopes,1,2 Suzette J Bielinski,2 Ann M Moyer,3 John Logan Black III,3 Debra J Jacobson,1 Ruoxiang Jiang,1 Nicholas B Larson,1 Jennifer L St Sauver2

1Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; 2Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; 3Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

Correspondence: Guilherme S LopesDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USATel +1 507 422 6094Email lopes.guilherme@mayo.edu

Background: Several small studies have previously investigated associations between the cytochrome P450 2D6 (CYP2D6) metabolism and response to opioids. We used a large sample of patients to study associations between CYP2D6 phenotypes and estimated CYP2D6 enzymatic activity scores with pain control and adverse reactions related to codeine and tramadol use. We conducted additional analyses to determine whether our results were consistent among men and women.Methods: We used data from 2,877 participants in the RIGHT Protocol who were prescribed codeine and/or tramadol between 01/01/2005 and 12/31/2017 and who were not prescribed CYP2D6 inhibitors within 1 year prior to the opioid prescription. CYP2D6 phenotype categories were condensed into four groups: (1) Ultra-rapid and Rapid (n = 61), (2) Normal and Intermediate to Normal (n = 1,448), (3) Intermediate and Intermediate to Poor (n = 1,175), and (4) Poor metabolizer status (n = 193). Opioid-related outcomes included indications of poor pain control or adverse reactions related to medication use. We modeled the risk of each outcome using logistic regression, adjusting for age, sex, race, and ethnicity.Results: The results revealed a trend from poor to ultra-rapid and rapid CYP2D6 phenotypes in which the risk of adverse reactions incrementally increased and the risk of poor pain control incrementally decreased. This trend reached statistical significance among female (but not male) participants. Among normal and intermediate to normal metabolizers, a larger proportion of women experienced adverse reactions relative to men.Discussion: We replicated and extended the findings of previous research indicating associations between CYP2D6 phenotypes and response to opioids. In addition, the observed associations were stronger in women than in men. We recommend sex differences to be factored in future research investigating associations between pharmacogenomics and response to medications.

Keywords: opioids, codeine, tramadol, pharmacogenomics, sex differences, CYP2D6

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continue reading here:
Sex Differences in Associations Between CYP2D6 Phenotypes and Response | PGPM - Dove Medical Press

Insights Into the World’s Red Biotechnology Market, 2017-2019 & 2027 – Emerging Opportunities, Revenue Projections, Leading Players – PRNewswire

Posted on by

DUBLIN, Dec. 17, 2019 /PRNewswire/ -- The "Red Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

This study on the red biotechnology market provides readers with a holistic market overview, through an extensive analysis of the market.

The report analyzes the market with regards to the historical and current data to provide a forecast for the period of 2019-2027. Actionable insights and findings pertaining to the red biotechnology market help report readers take major business decisions that support their long-term business growth.

The study includes the compilation of the assessment of significant market dynamics such as key industry trends and major developments carried out by leading players, along with a detailed competitive assessment. The study is divided into key sections to provide readers with an individual understanding of the various aspects of the red biotechnology market.

Key Questions Answered

Key Topics Covered

1. Global Red Biotechnology Market - Preface1.1. Market Definition and Scope1.2. Market Segmentation1.3. Key Research Objectives1.4. Research Highlights

2. Assumptions and Research Methodology2.1. Red Biotechnology Market Definition2.2. Red Biotechnology Market Taxonomy

3. Executive Summary : Global Red Biotechnology Market3.1. Introduction3.1.1. Definition3.1.2. Industry Evolution/Developments3.2. Overview3.3. Market Dynamics3.3.1. Drivers3.3.2. Restrains3.3.3. Opportunities3.4. Global Red Biotechnology Market Analysis and Forecast, 2017-20273.5. Market Revenue Projections (US$ Bn)4. Market Outlook4.1. Pipeline Analysis4.2. Mergers & Acquisitions

5. Global Red Biotechnology Market Analysis and Forecast, by Application 5.1. Introduction5.2. Key Findings/Developments, by Type 5.3. Global Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2017-20275.3.1. Biopharmaceutical Production5.3.2. Gene Therapy5.3.3. Pharmacogenomics5.3.4. Genetic Testing5.4. Global Red Biotechnology Market Attractiveness Analysis, by Application

6. Global Red Biotechnology Market Analysis and Forecast, by End-user 6.1. Introduction6.2. Key Findings/Developments, by End-user 6.3. Global Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2017-20276.3.1. Pharmaceutical Industry 6.3.2. CMO & CRO6.3.3. Research Institutes6.3.4. Others 6.4. Global Red Biotechnology Market Attractiveness Analysis, by End-user

7. Global Red Biotechnology Market Analysis and Forecast, by Region/sub-Region7.1. Key Findings/Developments 7.2. Global Red Biotechnology Market Value (US$ Bn) Forecast, by Region/Sub-Region, 2017-20277.2.1. North America7.2.2. Europe7.2.3. Asia-Pacific 7.2.4. Latin America7.2.5. Middle East & Africa (MEA)7.3. Global Red Biotechnology Market Attractiveness Analysis, by Region/Sub-Region

8. North America Red Biotechnology Market Analysis and Forecast

9. Europe Red Biotechnology Market Analysis and Forecast

10. Asia-Pacific Red Biotechnology Market Analysis and Forecast

11. Latin America Red Biotechnology Market Analysis and Forecast

12. Middle East & Africa Red Biotechnology Market Analysis and Forecast

13. Competition Landscape13.1. Market Player - Competition Matrix 13.2. Market Share Analysis, by Company (2018)13.3. Company Profiles13.3.1. Pfizer Inc.13.3.2. Biogen Inc.13.3.3. Amgen Inc.13.3.4. AstraZeneca PLC13.3.5. Gilead Sciences Inc.13.3.6. Celgene Corporation13.3.7. F. Hoffmann-La Roche Ltd.13.3.8. Merck KGaA13.3.9. Regeneron Pharmaceuticals Inc.13.3.10. Takeda Pharmaceutical Company Limited

For more information about this report visit https://www.researchandmarkets.com/r/xf6hwp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more here:
Insights Into the World's Red Biotechnology Market, 2017-2019 & 2027 - Emerging Opportunities, Revenue Projections, Leading Players - PRNewswire

The global modular laboratory automation market at a CAGR of over 6% during the forecast period – P&T Community

Posted on by

NEW YORK, Dec. 26, 2019 /PRNewswire/ --

Global Modular Laboratory Automation Market: About this market This modular laboratory automation market analysis considers sales from hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, and other end-users. Our study also finds the sales of modular laboratory automation in Asia, Europe, North America, and ROW. In 2019, the hospitals and diagnostic laboratories segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing prevalence of chronic and infectious diseases such as cancer, diabetes, influenza, and cardiovascular will play a significant role in the hospitals and diagnostic laboratories segment to maintain its market position. Also, our global modular laboratory automation market report looks at factors such as increasing workload in clinical and diagnostic laboratories, and demand for automation among reference laboratories. However, implementation and integration of automated systems into existing laboratory space, requirement for high capital investments, and risk of prolonged downtime due to automation failure may hamper the growth of the modular laboratory automation industry over the forecast period.

Read the full report: https://www.reportlinker.com/p05834273/?utm_source=PRN

Global Modular Laboratory Automation Market: Overview Rising drug development and research activities The drug R&D sector is witnessing rapid growth with the increase in drug discovery activities and approvals. Drug discovery activities involve safety testing procedures such as validation testing, pharmacogenomic testing, and toxicity testing. This is encouraging drug development researchers to use automation technologies, which are used in safety testing procedures to automate the preanalytical and post-analytical processing. It enhances the process by developing a streamlined workflow and minimizing manual intervention. Thus, the rise in drug development and research activities will lead to the expansion of the global modular laboratory automation market at a CAGR of over 6% during the forecast period. Integration of AI and analytical tools in laboratory workflow Vendors are finding automation and Al as complementing technologies that are together ensuring the optimum utilization of laboratory resources and helping in increasing productivity. The integration of Al and analytical tools has resulted in the introduction of smart modular laboratory automation solutions, which have allowed easy, reliable, and secured networking of automated modules at the field level. Additionally, features such as intelligent control and real-time update about the economic consumption of water and raw materials help provide significant cost benefits to the laboratories deploying such smart systems. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape With the presence of a few major players, the global modular laboratory automation market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading modular laboratory automation manufacturers, that include Agilent Technologies Inc., Becton, Dickinson and Co., Bio-Rad Laboratories Inc., Danaher Corp., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., QIAGEN NV, Shimadzu Corp., Siemens AG, and Thermo Fisher Scientific Inc. Also, the modular laboratory automation market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Read the full report: https://www.reportlinker.com/p05834273/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-modular-laboratory-automation-market-at-a-cagr-of-over-6-during-the-forecast-period-300979382.html

SOURCE Reportlinker

Read more from the original source:
The global modular laboratory automation market at a CAGR of over 6% during the forecast period - P&T Community

Data from NantHealths GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer patients – Yahoo Finance

Posted on by

NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium

NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients during a poster session at the 2020 Gastrointestinal Cancer Symposium sponsored by the American Society of Clinical Oncology (ASCO).

The Symposium, held at the Moscone West Building in San Francisco, CA from January 23-25, provides evidence-based teaching methods and cutting-edge learning science to a diverse audience of leaders in oncology education, doctors and care teams.

NantHealths presentation utilized data on whole exome (WES) DNA tumor and paired germline and matched deep whole transcriptomic sequencing (RNA-Seq) to identify a higher percentage of CRC patients with HER2 signaling than conventional methods of immunohistochemistry (IHC) or fluorescence in-situ hybridization (FISH). ERBB2 (HER2) gene expression was evaluated using NantOmics Nant50 gene classifier, which separates patients into subgroups that have been well established in breast cancer. The application of this tool to colorectal cancer proved surprising with greater than expected HER2 positive patients with a normally expected distribution of CMS classification (consensus molecular subtype in CRC). This finding suggests a possible utility for this tool in a new clinical setting. In addition, the HER2 enriched group did not show differentially expressed mutations in other targetable genes such as PIK3CA and BRAF, highlighting the potential importance of HER2 targeting in this population.

"Our analysis shows that conventional testing methods may miss potentially actionable HER2 signaling in CRC patients," said Sandeep "Bobby" Reddy, MD, Chief Medical Officer, NantHealth. "The significant difference suggests that up to 40% more patients may be eligible for HER2 directed therapies, which has implications for drug development and clinical trials."

Title: "Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients"

Authors: Sandeep K. Reddy, M.D., Tara Elisabeth Seery, M.D., Christopher W. Szeto, Ph.D.

Poster Session and Number: Poster session C (Board #A14)

Location: Moscone West Building

Date and Time: January 25, 2020, 6:30-7:55 AM PT and 12:15-1:45 PM PT

About NantHealth:

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealths comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti), connected care solutions that deliver medical device interoperability (DCX device connectivity platform and VCX patient vitals software) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer). For more information, please visit http://www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

About NantOmics:

NantOmics, a member of the NantWorks ecosystem of companies, invented and developed the technologies that drive NantHealths GPS Cancer platform. GPS Cancer provides actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing molecular variances and profiles that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances from DNA to RNA to protein to drug. Having pioneered tumor-normal DNA sequencing and introduced whole RNA transcriptomic analysis to better inform clinical treatment decisions, NantOmics has provided molecular insights for thousands of cancer patients.

NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time and correlating proteomic pathway analysis with quantitative gene expression and pharmacogenomic signatures, which guides the use of immunotherapies, chemotherapies and targeted therapies. Clinical studies for neoepitope vaccines using NantOmics proprietary technologies and novel artificial intelligence platforms are currently underway. For more information please visit http://www.nantomics.com.

Story continues

Forward-Looking Statements: NantHealth

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on managements current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200125005009/en/

Contacts

NANT Jen HodsonJen@nant.com 562-397-3639

Read more here:
Data from NantHealths GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer patients - Yahoo Finance

Genealogy Products and Services Market Demand for Genetic Testing to Surge as Preventive Healthcare and Pharmacogenomics Gain Traction – Young…

Posted on by

Global Genealogy Products and Services Market A Report by Fact.MR

Fact.MR, in its latest business intelligence study, depicts the nuts and bolts of the global genealogy products and services market. The genealogy products and services market report presents detailed information regarding the drivers, restraints, opportunities and trends affecting market growth. Each segment along with its sub-segment is analyzed in terms of value and volume. Further, the genealogy products and services market report elaborates the market behavior of each vendor operating in the genealogy products and services market.

The genealogy products and services market report considers the following years to present the overall market growth:

Key findings of the genealogy products and services market study:

Request Sample Report https://www.factmr.com/connectus/sample?flag=S&rep_id=3083

On the basis of category, the genealogy products and services market study consists of:

On the basis of region, the genealogy products and services market study contains:

Key players analyzed in the genealogy products and services market study:

Queries addressed in the genealogy products and services market report:

Request Methodology of this Report https://www.factmr.com/connectus/sample?flag=RM&rep_id=3083

Why choose Fact.MR?

Reports published by Fact.MR are a result of the combination of our experts and digital technologies. We thrive to provide innovative business solutions to the clients as well as tailor the reports aligning with the clients requisites. Our analysts perform comprehensive research to offer ins and outs of the current market situation. Clients across various time zones tend to utilize our 24/7 service availability.

See the original post:
Genealogy Products and Services Market Demand for Genetic Testing to Surge as Preventive Healthcare and Pharmacogenomics Gain Traction - Young...

Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019 – Yahoo Finance

Posted on by

PARSIPPANY, NJ, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss the Companys financial results and provide a general business update.

All listeners should confirm they are dialing in for the Interpace conference call with the operator who will promptly place them into the call. A webcast replay will be available on the companys website (www.interpacediagnostics.com) approximately two hours following completion of the call and will be archived on the companys website for 90 days.

About Interpace, Inc.

Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpaces Diagnostic Business is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDXthat differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Interpaces Biopharma Business is a market leader in providing pharmacogenomics testing, genotyping, and biorepository services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpaces website at http://www.interpacediagnostics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Story continues

CONTACTS:Investor Relations - Edison GroupJoseph Green(646) 653-7030jgreen@edisongroup.com

Visit link:
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019 - Yahoo Finance

Pharmacogenomics Market be Impacted by Rising Adoption of Automated Diagnostic Devices in Healthcare Industry – Industry Updates Daily

Posted on by

The market research reportPharmacogenomics Marketevaluates the historical, the latest values and current changes to predict the market for the coming years from 2019 to 2026.

Our specific research examiners have been prepared to direct their exploration needs to the right research assets and to add a unique advantage over their rivals. We give scholarly, precise and important information in the lightning.

The main actors focus their efforts on developing ongoing innovations aimed at improving skills and realistic turnaround times. The best long-term development opportunities for this area can be captured by ensuring continuous process upgrades and adaptability with financial resources to put resources in the right methodologies.

Get HOLISTIC Request Sample Copy:https://www.coherentmarketinsights.com/insight/request-sample/1053

The report allows you to:

Recognize and learn from important and distinct types of underdevelopment

Formulate competitor reports, market analyzes and significant information to improve R & D strategies

Develop tactics for market entry and market expansion

Plan Mergers and Acquisitions Effectively by Identifying Key Players in the Most Promising Pipeline

This market report should develop within the estimated time frame, with the compound annual growth rate increasing considerably. The aim of the market research report is to determine the current state of the global market for Pharmacogenomics and, according to this ranking, classify it into a few parts. The report takes into account the main players in the industry in all areas of the world.

Reasons to invest in this report:

Develop / modify small business development strategies using substantial growth offering emerging and developed markets.

Highlights key industry priorities to help organizations realign their business strategies.

Save less time to undertake an entry-level study by identifying the extension, dimensions, major players, and sections.

Encourage the decision-making process in the global market by including projects that demonstrate commercial interest in services and products, segmentation and vertical markets.

Has studied global trends and forecasts of the global market, as well as all the factors that direct the current activity, in addition to those that endanger it.

Download PDFBrochure withIn-Depth Study of TOC: https://www.coherentmarketinsights.com/insight/request-pdf/1053

About us:

Coherent Market Insights is a leading market research and advisory firm offering ready-made underwriting research reports, customized market research, consulting and competitive analysis through a variety of industry trend recommendations. emerging markets, technologies and potential opportunities in absolute dollars.

Link:
Pharmacogenomics Market be Impacted by Rising Adoption of Automated Diagnostic Devices in Healthcare Industry - Industry Updates Daily

Drug-Gene Testing – Center for Individualized Medicine …

Posted on by

Drugs and Genes Conference

The right drug at the right dose at the right time

Drug-gene testing is also called pharmacogenomics, or pharmacogenetics. All terms characterize the study of how your genes affect your body's response to medications. The word "pharmacogenomics" is combined from the words pharmacology (the study of the uses and effects of medications) and genomics (the study of genes and their functions).

Your body has thousands of genes that you inherited from your parents. Genes determine which characteristics you have, such as eye color and blood type. Some genes are responsible for how your body processes medications. Pharmacogenomic tests look for changes or variants in these genes that may determine whether a medication could be an effective treatment for you or whether you could have side effects to a specific medication.

Patient Information: Pharmacogenomics Finding the Right Medication for You

Pharmacogenomic testing is one tool that can help your health care provider determine the best medication for you. Your health care provider also considers other factors such as your age, lifestyle, other medications you are taking and your overall health when choosing the right treatment for you.

The Pharmacogenomics Program investigates how variations in genes affect response to medications, thereby using a patient's genetic profile to predict a drug's efficacy, guide dosage and improve patient safety.

The purpose of pharmacogenomic testing is to find out if a medication is right for you. A small blood or saliva sample can help determine:

The laboratory looks for changes or variants in one or more genes that can affect your response to certain medications.

Each person would need to have the same specific pharmacogenomic test only once because your genetic makeup does not change over time. However, you may need other pharmacogenomics tests if you take another medication. Each medication is associated with a different pharmacogenomics test. Keep track of all your test results and share them with your health care providers.

The need for pharmacogenomics testing is determined on an individual basis. If your pharmacogenomic test results suggest you may not have a good response to a medication, your family members may have a similar response. Mayo Clinic recommends you share this information with your family members. Your health care provider can also provide recommendations for family members who may benefit from having testing.

Genomic sequencing is a process for analyzing a sample of DNA taken from your blood. In the lab, technicians extract DNA and prepare it for sequencing.

Applied pharmacogenomics resolves patient's lifelong anxiety and depression.

Current limitations of pharmacogenomics testing include:

The cost of pharmacogenomics testing varies depending on which test is ordered and your health insurance coverage. To help you determine test costs and coverage:

A federal law called the Genetic Information Nondiscrimination Act (GINA) generally makes it illegal for health insurance companies to discriminate against you based on your genetic information. This federal law does not protect you against genetic discrimination by life insurance, disability insurance or long-term care insurance companies. Some states have laws in this area.

.

See the article here:
Drug-Gene Testing - Center for Individualized Medicine ...

Pharmacogenetic Tests | LabCorp

Posted on by

Why is pharmacogenetics important?

When initiating drug therapy to treat a particular condition, healthcare practitioners typically prescribe one of several appropriate drugs. Dosages and timing of drugs are usually based upon the anticipated rate of metabolism and clearance from the body in the average person. They prescribe a "standard" dose based on factors such as weight, sex, and age. Clinically, however, each person responds uniquely to treatment and healthcare practitioners must make adjustments. For example, the healthcare practitioner may adjust the drug dose or switch to a different therapy, depending on whether the person's condition is responding to the medication and whether the individual is experiencing unpleasant or dangerous side effects. Sometimes a person may find that a treatment that has been working well suddenly causes symptoms when that person starts taking an additional drug.

The concentrations or effects of some drugs are monitored with blood tests and the drug dosages may be increased or decreased to maintain the drug level in an established therapeutic range. Follow-up of drug concentration is called therapeutic drug monitoring. If changing the drug dose is not effective in treating or controlling the person's condition, or the person still has side effects, then the person may be given a different drug.

In contrast, pharmacogenetics offers healthcare providers the opportunity to individualize drug therapy for people based on their genetic make-up. Testing people prior to initiating drug therapy to determine their likely response to different classes of drugs is a key emerging area of testing. Such genetic information could prove useful to both the healthcare practitioner and patient when choosing current and future drug therapies and drug doses. For certain medications, pharmacogenetics is already helping healthcare providers predetermine proper therapies and dosages to have a better chance of achieving the desired therapeutic effect while reducing the likelihood of adverse effects.

Genes are the basic units of genetic material, the segments of DNA that usually code for the production of specific proteins, including the proteins known as enzymes. Each person has two copies of most genes: one copy is inherited from the person's mother and one copy is inherited from the person's father. Each gene is made up of a specific genetic code, which is a sequence of nucleotides (A, T, G, or C). For each nucleotide position in the gene, one of the four nucleotides is the predominant nucleotide in the general population. This nucleotide is usually referred to as "wild type." If an individual has a nucleotide that is different from "wild type" in one copy of his or her genes, that person is said to have a heterozygous variant. If an individual has the same variant nucleotide in both copies of his or her genes, that person is said to have a homozygous variant.

Nucleotide or genetic variants (also called polymorphisms or mutations) occur throughout the population. Some genetic variants are benigndo not produce any known negative effect or may be associated with features like height, hair color, and eye color. Other genetic variants may be known to cause specific diseases. Other variants may be associated with variable response to specific medications.

Pharmacogenetic tests look for genetic variants that are associated with variable response to specific medications. These variants occur in genes that code for drug-metabolizing enzymes, drug targets, or proteins involved in immune response. Pharmacogenetic tests have the ability to determine if a variant is heterozygous or homozygous, which can impact an individual's response or reaction to a drug.

A healthcare practitioner may test a patient's genes for certain variations that are known to be involved in variable response to a medication at any time during treatment (for example, prior to treatment, during initial phase of treatment, or later in the treatment). The results of the testing may be combined with the individual's clinical information, including age, weight, health and other drugs that they are taking, to help tailor therapy. Sometimes, the healthcare practitioner may use this information to adjust the medication dose or sometimes to choose a different drug. Pharmacogenetic testing is intended to give the healthcare practitioner additional information but may not replace the need for therapeutic drug monitoring.

Pharmacogenetic testing for a specific gene is only performed once since a person's genetic makeup does not change over time. Depending on the medication, a single gene may be ordered or multiple genes may be ordered. An example of a medication for which multiple genes are usually evaluated is warfarin, which can be affected by genetic variation in CYP2C9 and VKORC1.

Testing may be ordered prior to starting specific drug therapies or if a person who has started taking a drug is experiencing side effects or having trouble establishing and/or maintaining a stable dose. Sometimes a person may not experience such issues until other medications that affect the metabolism or action of the drug in question are added or discontinued.

Pharmacogenetic testing is available for a relatively limited number of drugs. Some tests may only be applicable to specific ethnic groups. The following are examples of some drugs for which pharmacogenetic tests are available:

Currently they are only indicated if a person is going to take, or is taking, a drug that has an accepted pharmacogenetic test associated with it.

No. The FDA may recommend this testing, as in the case of irinotecan, but it is not required.

Your genetic make-up does not change over time. You may, however, have other pharmacogenetic tests performed if you take a different drug with a different associated pharmacogenetic test.

No. Since there are other factors that affect drug levels besides your genetics, therapeutic drug monitoring may still be necessary.

A blood sample is obtained by inserting a needle into a vein in the arm. Saliva samples and buccal swabs, collected by brushing the inner side of the cheek with a swab, can also be used.

Pharmacogenetic tests are performed to evaluate a person's potential response to a drug therapy. Most genetic tests have been developed to help diagnose or predict the development of a genetic disease, for forensic medicine purposes, and in establishing parentage. Another common use of genetic testing is to detect the genetic material (DNA or RNA) of bacteria and viruses to help diagnose an infection. (Read the article The Universe of Genetic Testing for more information.)

You may be monitored differently depending on the results of the test, especially when starting the medication, changing the dose, or when adding or discontinuing another medication.

This is a question to discuss with your healthcare provider and your family members. In some cases it may be useful; in others it may only be relevant if they are going to be taking the same drug or a drug in the same class. Pharmacogenetic test results are useful information for a family member to share with the healthcare practitioner along with the family's medical history.

You and your healthcare provider should consider the condition that you have, your history of drug-related side effects and/or adverse drug reactions, the drug therapies that are available, and the uses the test is intended for. Pharmacogenetic tests are not meant to stand alone but are meant to be used in conjunction with your other clinical findings.

Pharmacogenetic testing is available for a relatively limited number of medications. Pharmacogenetics tests are generally not widely used and not all insurers will cover their cost. Individuals should consult with their healthcare practitioners about these issues.

Pharmacogenetic tests are intended to provide the healthcare practitioner and patient with additional information when selecting drug treatments and dosages. For a better understanding, patients may want to consult with a genetic counselor prior to and after having a pharmacogenetic test performed. Genetic counseling and informed consent are recommended for all genetic testing.

To learn more about the role of pharmacogenetics in personalized medicine, visit the Personalized Medicine Coalition website.

The rest is here:
Pharmacogenetic Tests | LabCorp

Pharmacogenomics and Personalized Medicine – Dove Press

Posted on by

- 183 records -

Original Research

Galvez JM, Restrepo CM, Contreras NC, Alvarado C, Caldern-Ospina CA, Pea N, Cifuentes RA, Duarte D, Laissue P, Fonseca DJ

Pharmacogenomics and Personalized Medicine 2018, 11:169-178

Published Date: 16 October 2018

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:167-168

Published Date: 26 September 2018

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:127-137

Published Date: 25 July 2018

Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J

Pharmacogenomics and Personalized Medicine 2018, 11:95-106

Published Date: 8 June 2018

Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO

Pharmacogenomics and Personalized Medicine 2018, 11:43-49

Published Date: 22 March 2018

Original Research

St Sauver JL, Olson JE, Roger VL, Nicholson WT, Black III JL, Takahashi PY, Caraballo PJ, Bell EJ, Jacobson DJ, Larson NB, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:217-227

Published Date: 24 July 2017

Zastrozhin MS, Brodyansky VM, Skryabin VY, Grishina EA, Ivashchenko DV, Ryzhikova KA, Savchenko LM, Kibitov AO, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:209-215

Published Date: 7 July 2017

Chidambaran V, Zhang X, Martin LJ, Ding L, Weirauch MT, Geisler K, Stubbeman BL, Sadhasivam S, Ji H

Pharmacogenomics and Personalized Medicine 2017, 10:157-168

Published Date: 9 May 2017

Mirzaev KB, Zelenskaya EM, Barbarash OL, Ganyukov VI, Apartsin KA, Saraeva NO, Nikolaev KY, Ryzhikova KA, Lifshits GI, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:107-114

Published Date: 12 April 2017

Original Research

Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA, Snalina NE, Sozaeva ZA, Grabuzdov AM, Matsneva IA

Pharmacogenomics and Personalized Medicine 2017, 10:93-99

Published Date: 31 March 2017

Review

Prince AER, Cadigan RJ, Henderson GE, Evans JP, Adams M, Coker-Schwimmer E, Penn DC, Van Riper M, Corbie-Smith G, Jonas DE

Pharmacogenomics and Personalized Medicine 2017, 10:49-60

Published Date: 20 February 2017

Original Research

Takahashi PY, Ryu E, Pathak J, Jenkins GD, Batzler A, Hathcock MA, Black JL, Olson JE, Cerhan JR, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:39-47

Published Date: 14 February 2017

Original Research

Frick A, Fedoriw Y, Richards K, Damania B, Parks B, Suzuki O, Benton CS, Chan E, Thomas RS, Wiltshire T

Pharmacogenomics and Personalized Medicine 2015, 8:81-98

Published Date: 26 February 2015

Original Research

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML

Pharmacogenomics and Personalized Medicine 2014, 7:163-171

Published Date: 14 July 2014

Review

Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA

Pharmacogenomics and Personalized Medicine 2013, 6:25-36

Published Date: 4 April 2013

Go here to see the original:
Pharmacogenomics and Personalized Medicine - Dove Press

Quest Diagnostics : Pharmacogenomics

Posted on by

Quest Diagnostics offers one of the most comprehensive pharmacogenomics test panels available to help you gain insight into a patients potential response to medications and optimize their treatment considerations and outcomes. This includes information for over 280 drugs across 44 genes*. This full panel is particularly advantageous for patients on multiple medications who may otherwise require multiple panelsall at a low cost and coming from a company you trust to meet all of your lab needs.

The Pharmacogenomics Panel from Quest provides pharmacogenetic information for 44 genes, and reports information across multiple classes of medications:

Physicians receive test results in a comprehensive and easy to understand report that may include dosing guidelines from CPIC, FDA-approved labeling, and other pharmacogenomic consortia. Results can be utilized as a reference for your patients throughout their lifetime.

Order Pharmacogenomics PGx panel today.

The Quest Diagnostics Pharmacogenomics Panel is based on pertinent literature sources that may provide clinical insights to help inform treating physicians about a patients genetic attributes to help optimize patient treatment considerations and outcomes.**

Pharmacogenetics/pharmacogenomics is the study of how inherited genetic differences impact the way drugs or medications affect a person. These genetic differences can impact the way a drug is absorbed or metabolized and thereby influence drug response. Pharmacogenomic tests may provide information about a persons genetic makeup to help doctors decide which medications and doses might work best for him or her. Pharmacogenomic testing can also help reduce the time and costs associated with a trial-and-error approach to treatment.1

Avoiding adverse drug reactions can make a difference

The Quest Diagnostics comprehensive pharmacogenomics test panel (PGx) offers insights into patient potential responses to different medications and over 280 drugs.*

The panel may determine:

A Pharmacogenomics Panel may provide additional insights to:

*Pharmacogenomic information is not assessed for potential alternative medications. These data are provided as alternatives to consider based on information reported in the literature due to pharmacogenomic contraindications in other medications.

**Sources available upon request.

DNA will be extracted from the sample and tested for changes in multiple genes.

***The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Download PGx brochure.

Download PGx medication and gene list.

Download PGx Report guide.

Download Patient informed consent form.

Ordering steps

****Get copies of the paper Pharmacogenomics requisition from your Quest Diagnostics account manager.

The information provided herein and in the pharmacogenetics report is for physician consideration and each physician has to determine what is the best treatment for their patient based upon the physicians education, experience, and clinical assessment of the patient.

References

Link:
Quest Diagnostics : Pharmacogenomics